Bruno Coudert
机构: Centre Georges Francois Leclerc Dijon France
每年引用次数
引用次数
引用: 17,349
H-指数: 60
I10-指数 : 124
出版物: 426
PCN97 COST EFFECTIVENESS OF ERLOTINIB TREATMENT GIVEN BY A CLINICALLY BASED APPROACH AND AN EGFR/KRAS TESTING-GUIDED APPROACH ADVANCED IN NON SMALL-CELL LUNG CANCER: A PROSPECTIVE MULTICENTRIC FRENCH STUDY (ERMETIC)
I Borget , J Cadranel , JP Pignon , G Danton
Value in Health 12 ( 7)
2009
It is time for chronotherapy
B Coudert , G Bjarnason , C Focan , E.Donato di Paola
Pathologie Biologie 51 ( 4) 197 -200
10
2003
Dear Readers, We hope that you have enjoyed the articles published in Drugs in R&D in 2005. We are pleased to have been able to provide such varied and topical articles. As always, we would be pleased to consider any high-quality review articles and original research articles that you care to submit
A Agarwal , A Lenzi , B Aran , F Levi
2005
Bouchier-Hayes, DJ, 297 Bruix, J., 99
AU Buzdar , MS Cairo , G Carrum , E Cellarier
Phase II Trial of Chronomodulated Infusion of High-Dose Fluorouracil and l-Folinic Acid in Previously Untreated Patients With Metastatic Colorectal Cancer
H Cure , V Chevalier , A Adenis , N Tubiana-Mathieu
Journal of Clinical Oncology 20 ( 5) 1175 -1181
21
2002
ORIGINAL REPORTS-Gastrointestinal Oncology-Phase II Trial of Chronomodulated Infusion of High-Dose Fluorouracil and l-Folinic Acid in Previously Untreated Patients With Metastatic Colorectal
H Cure , V Chevalier , A Adenis , N Tubiana-Mathieu
Journal of Clinical Oncology 20 ( 5) 1175 -1181
2002
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication
D Miles , E Ciruelos , A Schneeweiss , F Puglisi
Annals of Oncology 32 ( 10) 1245 -1255
48
2021
Defining the revisit frequency for the MISTIGRI project of a satellite mission in the thermal infrared
Jean-Pierre Lagouarde , Albert Olioso , G Boulet , B Coudert
Third Recent Advances in Quantitative Remote Sensing (RAQRS), Torrent (Valencia, Spain) 27 824 -829
6
2010
Comparing prediction performances of 18 F-FDG PET and CGFL/Curie nomogram to predict pathologic complete response after neoadjuvant chemotherapy for HER2-positive breast cancers
L Vincent , C Jankowski , L Arnould , B Coudert
Gynecologie, Obstetrique, Fertilite & Senologie 48 ( 9) 679 -686
2020
Pathological complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER2 amplification in locally advanced breast cancer.
L Arnould , M Gelly-Marty , J Couturier , E Ferrant
BREAST CANCER RESEARCH AND TREATMENT 100 S49 -S49
1
2006
Benefit of neoadjuvant capecitabine plus epirubicin plus cyclophosphamide (CEX) versus 5-FU+ epirubicin plus cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T)
D Berton-Rigaud , H Roche , F Penault-Llorca , N Tubiana-Mathieu
JOURNAL OF CLINICAL ONCOLOGY 26 ( 15)
2008
Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
C Massard , JJ Voigt , A Laplanche , S Culine
British Journal of Cancer 99 ( 11) 1959 -1959
2008
Standards, Options: Recommandations pour I’indication des agents stimulant l’érythropoïèse (ASE: époétine alpha, époétine bêta et darbépoétine) dans la prise en charge de l’anémie en cancérologie (mise à jour 2007), rapport abrégé
I Ray-Coquard , D Kassab-Chahmi , N Casadevall , P Chastagner
Oncologie 10 ( 2) 160 -166
3
2008
FICHE-YOUNG: FIrst-line treatment CHoicE in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer patients (MBC)≤ 45 years old. A large observational multicenter cohort survival analysis
B Pistilli , A Lardy-Cleaud , E Jacquet , S Delaloge
Annals of Oncology 28 v92 -v93
3
2017
Survival of patients with aromatase inhibitors sensitive, HR+/HER2-metastatic breast cancer treated with a first-line endocrine therapy or chemotherapy in a multicenter national observational study
E Jacquet , A Lardy-Cleaud , B Pistilli , P Cottu
Annals of Oncology 28 v86 -v86
2017
Infiltrats immunologiques et chimiothérapie néoadjuvante
F Ghiringhelli , L Arnould , B Coudert , P Fumoleau
La Lettre du sénologue ( 47) 34 -35
2010
Phase II trial of chronomodulated high dose 5-fluorouracil and L-folinic acid in patients with metastatic colorectal cancer
H Curé , A Adenis , N Tubiana-Mathieu , R Ouabdesselam
PROCEEDINGS OF THE ANNUAL MEETING-AMERICAN SOCIETY OF CLINICAL ONCOLOGY 17 1048 -1048
5
1998
Etude de la valeur diagnostique et predictive des tests cutanes dans l'hypersensibilite immediate aux sels de platine chez 21 patients
V Leguy-Seguin , E Collet , G Jolimoy , B Coudert
ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE 132 C62 -C62
2005
Multicentre phase II study of imatinib mesylate (Gleevec) in patients with recurrent glioblastoma: an EORTC NDDG/BTG intergroup study
MJ Van den Bent , AA Brandes , A Van Oosterom , C Dittrich
Neuro-oncology 6 383 -384
26
2004
RELATIONSHIP BETWEEN 4-IPOMEANOL METABOLISM AND P450IA1 GENE-EXPRESSION IN HUMAN-LUNG AND PULMONARY-CARCINOMA TISSUE
T McLemore , S Adelberg , C Litterst , B Coudert
CLINICAL RESEARCH 36 ( 3) A498 -A498
1
1988